01 Shift Toward Multi-Hormone Fertility Testing Devices The fertility testing devices market analysis shows growing adoption of multi-hormone testing systems that provide more detailed reproductive health information than conventional ovulation strips. Inito's Fertility Monitor measures four hormones, including LH, estrogen, FSH, and PdG, using a single test strip, supporting more comprehensive home-based fertility monitoring.
02 Preference for Smartphone-based Male Fertility Testing Smartphone-based sperm testing devices are gaining importance as men increasingly seek private and convenient fertility assessments. These devices use smartphone cameras and specialized analysis tools to measure sperm concentration and motility outside traditional laboratories. The technology supports quicker preliminary assessments and repeated monitoring at home.Supply chain disruptions are expected to have a moderate impact on the fertility testing devices market share due to shortages of diagnostic reagents, antibodies, test strips, and electronic components. The market is expected to experience a U-shaped recovery, as manufacturing delays and higher component costs may temporarily affect product availability. Established manufacturers with diversified suppliers are better positioned to maintain production, while smaller companies may face longer procurement delays. The market is projected to grow at a CAGR of 5.48%. Supply constraints could reduce short-term growth to 4.00% under an illustrative disruption scenario. Improved component availability and stable production are expected to support recovery toward 5.48%.The fertility testing devices market forecasts continued investment in home-based hormone monitoring, male fertility diagnostics, and advanced testing technologies.
03 Key Investment and Funding Activities in Fertility Testing Devices Market, 2025 Company Value (USD) Details Inito USD 29 Million In December 2025, Inito announced Series B funding to expand its at-home diagnostic platform and develop AI-engineered antibody technologies. Fellow Health USD 24 Million In September 2025, Fellow Health secured Series B funding to expand mail-in semen analysis services and strengthen its fertility testing network.
01 Use of Repeat Semen Analysis for Male Fertility Assessment and Cycle-Specific Fertility Testing in Assisted Reproduction Drives Market Clinical emphasis on repeated semen analysis is supporting demand for male fertility testing devices. Sperm concentration and motility can vary between samples, making repeat assessments important for reliable fertility evaluation. This is increasing the need for semen analysis systems in fertility clinics and diagnostic laboratories. Timed fertility assessments before assisted reproductive procedures is strengthening demand for fertility testing devices. Fertility specialists require accurate hormonal measurements to determine ovarian response and optimize treatment timing. This supports demand for estradiol and luteinizing hormone testing systems in fertility clinics. The need for repeated hormone measurements during ovarian stimulation also increases device utilization and supports consistent demand for clinical fertility testing equipment.
01 Limited Diagnostic Reliability of Single-Hormone Ovulation Tests and High Cost of Consumables Restrain Market Expansion Conventional ovulation predictor kits primarily detect luteinizing hormone surges rather than confirming successful ovulation. Hormonal fluctuations can produce misleading results, particularly among women with irregular menstrual cycles or polycystic ovary syndrome. The U.S. Food and Drug Administration states that these tests cannot confirm pregnancy or guarantee ovulation.High cost of fertility test strips and digital monitoring systems limits affordability for consumers requiring regular reproductive health assessment. Advanced fertility monitors may also require dedicated readers and replacement testing supplies. These expenses can discourage repeated testing, particularly in price-sensitive markets.
01 Development of Rapid Ovarian Reserve Testing Systems and Advancement of Tubal Patency Assessment Devices Offers Growth Opportunities Rapid anti-Müllerian hormone (AMH) testing systems offer opportunities for fertility testing device manufacturers. AMH measurements help fertility specialists predict ovarian response during assisted reproductive treatment. The European Society of Human Reproduction and Embryology's guideline recommends AMH or antral follicle count for predicting ovarian stimulation response. The advancement of ultrasound-based tubal patency assessment devices presents opportunities for fertility diagnostic equipment manufacturers. Hysterosalpingo-contrast sonography (HyCoSy) enables clinicians to examine fallopian tube patency using ultrasound imaging and contrast agents. The World Health Organization's infertility guideline recognizes HyCoSy as an option for investigating suspected tubal disease. This creates opportunities for specialized ultrasound accessories and compatible contrast delivery systems in fertility clinics seeking alternatives to X-ray-based examinations.